Hutchison China Meditech Ltd (HCM)

 

HCM Share PerformanceMore

52 week high3,690.00 21/06/17
52 week low1,760.00 25/08/16
52 week change 1,700.00 (90.67%)
4 week volume272,957 31/05/17

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Chi-Med starts clinical trial in China

Hutchison China MediTech has initiated a phase I/II clinical trial of HMPL453 in China. Chi-Med said HMPL453 was a nov...

Chi-Med starts Ph I/II Trial of HMPL 453 in China

RNS Number: 8432I Hutchison China Meditech Limited 22 June 2017 Press Release ChiMed Initiates a Phase I/II Clinical Trial of Novel FGFR Inhibitor HMPL453 in China London: Thursday , June 22, 2017: Hutchison China MediTech Limited ("ChiMed") (AIM/Nasdaq: HCM) has just initiated a Phase I/II clinical trial of HMPL453 in China. HMPL453 is a novel, highly...

Director's Share Dealing

RNS Number: 3179I Hutchison China Meditech Limited 16 June 2017 Director's Share Dealing London: Friday, June 16 , 2017: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) has received notifications that:- 1. Dynamic Drive Limited, a person closely associated ("PCA") with Mr Simon To, Executive Director and Chairman, purchased a total of 11,1...

Fruquintinib NDA for Advanced CRC Filed with CFDA

Miscellaneous medium priority announcements

Fruquintinib data highlighted at ASCO, says Chi-Med

Hutchison China MediTech said results from its pivotal phase III trial with fruquintinib, its novel vascular endothelial grow...

Phase III Fruquintinib Data presented at ASCO

RNS Number: 1575H Hutchison China Meditech Limited 06 June 2017 Press Release Chi-Med Highlights Phase III Fruquintinib Data in Oral Presentation atASCO Chicago: Monday, June 5, 2017: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) announced that results from its pivotal Phase III trial with fruquintinib, its novel vascular endothelial gr...

12 AIM shares in the 1,000% club

With AIM back near 1,000 for the first time in nine years, former AIM writer of the year Andrew Hore analyses the best ...

Broker Forecast - Panmure Gordon issues a broker note on Hutchison China Meditech Ltd

Panmure Gordon today reaffirms its buy investment rating on Hutchison China Meditech Ltd (LON:HCM) and raised its...

Equity Research (HCM)

edison investment research
Hutchison China MediTech Limited
13/06/2017
At ASCO, Hutchison China MediTech (HCM) presented detailed Phase III trial results for one of its leading assets, fruquintinib (third-line colorectal cancer). Full data from the China-based FRESCO...
edison investment research
Hutchison China MediTech Limited
13/06/2017
At ASCO, Hutchison China MediTech (HCM) presented detailed Phase III trial results for one of its leading assets, fruquintinib (third-line colorectal cancer). Full data from the China-based FRESCO...
edison investment research
Hutchison China MediTech Limited
11/05/2017
Despite a strong run over the last 12 months, our increased valuation of $2.7bn suggests the market overlooks HCM’s full R&D potential. Multiple catalysts are on the horizon in 2017/18; notably...

Latest discussion posts More

  • Re: DG

    Definitely a possibility. Only need to double our market cap to be almost level. I too, would like to thank you for your insight along with SI
    26-Jun-2017
    Maru118
  • Re: DG

    Thankyou sport! btw, my share price predictions are really just for my own benefit and also the enjoyment of seeing whether I am right or wide of the mark..... A big day ...
    20-Jun-2017
    David Global
  • DG

    DG, You have been posting very useful information about the company after researching several sources. Over the last several months, your predictions about HCM have been spot ...
    20-Jun-2017
    sporty investor

Users' HoldingsMore

Users who hold Hutchison China Meditech Ltd also hold..
RDS 'B'25%
NATIONAL GRID24%
LLOYDS GRP.18%
GLAXOSMITHKLINE18%
BP17%

Codes & Symbols

ISINKYG4672N1016
SymbolsHCM, LSE:HCM, HCM.L, HCM:LN, LON:HCM, XLON:HCM